crinecerfont
crinecerfont is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including Crenessity. Available dosage forms: solution, capsule.
Drug Details
- Generic Name
- crinecerfont
- Brand Names
- Crenessity
- Application Number
- NDA218820
- Sponsor
- Neurocrine Biosciences, Inc.
- NDC Codes
- 4
- Dosage Forms
- SOLUTION, CAPSULE
- Routes
- ORAL
- Active Ingredients
- CRINECERFONT
Indications and Usage
1 INDICATIONS AND USAGE CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH) . CRENESSITY is a corticotropin-releasing factor type 1 receptor antagonist indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).